Literature DB >> 10570434

The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells.

H Tanimoto1, L J Underwood, K Shigemasa, M S Yan Yan, J Clarke, T H Parmley, T J O'Brien.   

Abstract

BACKGROUND: Proteases play essential roles in the process of tumor invasion and metastasis. The serine protease stratum corneum chymotryptic enzyme (SCCE) has been purified from human stratum corneum and is known to contribute to the cell shedding process by catalyzing the degradation of intercellular cohesive structures at the skin surface. The presence of SCCE on the surface of tumor cells suggests it also may contribute to the process of tumor cell shedding, resulting in early metastasis of carcinoma.
METHODS: Gene expression of SCCE was investigated in 44 ovarian tumors (12 low malignant potential tumors and 32 carcinomas) and 10 normal ovaries by quantitative polymerase chain reaction (PCR). The PCR product was labeled with (32)P and a phosphoimager was used to determine the relative expression of SCCE compared with an internal control Beta-tubulin. mRNA transcripts were studied by Northern blot hybridization and protein expression and localization was examined by Western blot analysis and immunohistochemistry.
RESULTS: mRNA expression levels of SCCE were elevated significantly in 66.7% of 12 low malignant potential tumors and 78.1% of 32 carcinomas. Furthermore, SCCE protein was abundant in tumor cells and tumor cell lines that overexpressed the mRNA transcript.
CONCLUSIONS: The results of the current study suggest that SCCE frequently is overexpressed in ovarian tumors and therefore may contribute to tumor cell growth, tumor spread, and the metastatic potential of ovarian tumor cells. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10570434

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

Review 1.  Kallikreins - The melting pot of activity and function.

Authors:  Magdalena Kalinska; Ulf Meyer-Hoffert; Tomasz Kantyka; Jan Potempa
Journal:  Biochimie       Date:  2015-09-25       Impact factor: 4.079

2.  Crystallization and preliminary crystallographic studies of human kallikrein 7, a serine protease of the multigene kallikrein family.

Authors:  Israel S Fernández; Ludger Ständker; Wolf Georg Forssmann; Guillermo Giménez-Gallego; Antonio Romero
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-07-07

3.  A mutation in SNAP29, coding for a SNARE protein involved in intracellular trafficking, causes a novel neurocutaneous syndrome characterized by cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma.

Authors:  Eli Sprecher; Akemi Ishida-Yamamoto; Mordechai Mizrahi-Koren; Debora Rapaport; Dorit Goldsher; Margarita Indelman; Orit Topaz; Ilana Chefetz; Hanni Keren; Timothy J O'brien; Dani Bercovich; Stavit Shalev; Dan Geiger; Reuven Bergman; Mia Horowitz; Hanna Mandel
Journal:  Am J Hum Genet       Date:  2005-06-20       Impact factor: 11.025

4.  Proteolytic action of kallikrein-related peptidase 7 produces unique active matrix metalloproteinase-9 lacking the C-terminal hemopexin domains.

Authors:  Vishnu C Ramani; Gur P Kaushal; Randy S Haun
Journal:  Biochim Biophys Acta       Date:  2011-05-17

Review 5.  Cellular immunotherapy for ovarian cancer.

Authors:  Martin J Cannon; Timothy J O'Brien
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

6.  Chymotryptic specificity determinants in the 1.0 A structure of the zinc-inhibited human tissue kallikrein 7.

Authors:  Mekdes Debela; Petra Hess; Viktor Magdolen; Norman M Schechter; Thomas Steiner; Robert Huber; Wolfram Bode; Peter Goettig
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-01       Impact factor: 11.205

7.  The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.

Authors:  G M Yousef; A Scorilas; A Magklara; N Memari; R Ponzone; P Sismondi; N Biglia; M Abd Ellatif; E P Diamandis
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640

8.  Early detection biomarkers for ovarian cancer.

Authors:  Sreeja Sarojini; Ayala Tamir; Heejin Lim; Shihong Li; Shifang Zhang; Andre Goy; Andrew Pecora; K Stephen Suh
Journal:  J Oncol       Date:  2012-12-23       Impact factor: 4.375

9.  Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel.

Authors:  K Oikonomopoulou; L Li; Y Zheng; I Simon; R L Wolfert; D Valik; M Nekulova; M Simickova; T Frgala; E P Diamandis
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

10.  Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer.

Authors:  Vishnu C Ramani; Leah Hennings; Randy S Haun
Journal:  BMC Cancer       Date:  2008-12-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.